Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Lgd3.5
LGD-4033 (Ligandrol) – Forschung
Überwiegend Mechanismus / Beobachtung
6 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu LGD-4033 (Ligandrol) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 2013–2025 mit einer typischen Studiengröße von 2 Teilnehmenden.
Basierend auf 6 Studien · 1 RCT · 124 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Lean mass & body compositionEine 21-tägige Phase-1-RCT bei gesunden jungen Männern zeigte einen dosisabhängigen Anstieg der fettfreien Körpermasse ohne signifikante Veränderung der Fettmasse (testosteronsupprimierend; es existieren Fallberichte über schwere Leberschäden) · ~3 Wochen (Studiendauer)
Überwiegend Mechanismus / Beobachtung5 Studien
Testosterone & hormone suppression
Überwiegend Mechanismus / Beobachtung4 Studien
Liver health
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Cholesterol & lipids
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
3 Studien in den letzten 5 Jahren
201320192025
1Beobachtungsstudien=44 · small study2017
Einfach gesagt: Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine).
Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D · JAMA (2017)
Mandatory product-integrity counter-evidence: chemical analysis of 44 internet products sold as SARMs (including LGD-4033)
Only 52% contained any SARM; 39% contained a different unapproved drug (ibutamoren, GW501516, SR9009); 9% contained no active compound
The labelled amount matched the analysed content in only 41% of products; 59% differed substantially
Einfach gesagt: Lean body mass increased dose dependently ... LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels.
Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, et al. · The journals of gerontology. Series A, Biological sciences and medical sciences (2013)
The pivotal — and only — human RCT of LGD-4033: 76 healthy men randomised to placebo or 0.1, 0.3, or 1.0 mg daily for 21 days
Lean body mass increased dose-dependently with no significant change in fat mass; no drug-related serious adverse events over the short course
BUT dose-dependent suppression of total testosterone, SHBG, HDL cholesterol, and triglycerides, with free testosterone and FSH suppressed at the 1.0 mg dose
Einfach gesagt: Compounds representing the class of selective androgen receptor modulators (SARMs) are a relatively new group of substances that could be used in the future to improve the condition of patients with cachexia and frailty syndrome.
Borecki R, Byczkiewicz P, Słowikowska-Hilczer J · Endokrynologia Polska (2025)
Review framing the SARM class as investigational anabolic candidates for cachexia, sarcopenia, and frailty
Notes that the compounds furthest along in clinical trials are enobosarm (GTx-024/MK-2866) and GSK2881078 — not LGD-4033
Positions LGD-4033's lean-mass effect within an unproven, still-developmental therapeutic class
Einfach gesagt: The biopsy revealed canalicular cholestasis with ductopenia and periportal fibrosis ... a ligandrol-abuse could be determined as cause for the symptoms.
Einfach gesagt: We described a 32-year-old man who developed severe drug-induced liver injury after using Ligandrol (LGD-4033) ... liver biopsy that showed cholestatic hepatitis with a mild portal, periportal, and perisinusoidal fibrosis.
Barbara M, Dhingra S, Mindikoglu AL · ACG case reports journal (2020)
Counter-evidence on safety: a 32-year-old man developed severe drug-induced liver injury after using Ligandrol (LGD-4033)
Liver biopsy showed cholestatic hepatitis with mild portal, periportal, and perisinusoidal fibrosis
Notes that Ligandrol is available over the counter and via the internet despite not being an approved medicine
Einfach gesagt: We report two cases of liver injury in young men who used ligandrol and/or ostarine for a few weeks ... Histological evidence showed predominantly cholestatic injury with canalicular bile plugs, ductopenia, and mild hepatocellular damage.
Koller T, Vrbova P, Meciarova I, Molcan P, Smitka M, Adamcova Selcanova S · World journal of clinical cases (2021)
Two young men developed acute cholestatic liver injury after using ligandrol and/or ostarine for a few weeks, often with 'post-cycle therapy'
Clinical picture dominated by jaundice and fatigue; histology showed canalicular bile plugs, ductopenia, and mild hepatocellular damage
Both recovered after ~3 months; the off-target hepatotoxic effects of SARMs are emphasised against their misuse by amateur athletes